Trial Profile
Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Phenprocoumon
- Indications Pulmonary embolism; Stroke
- Focus Adverse reactions
- Acronyms IRIVASC
- 29 Aug 2022 Primary endpoint progression of coronary and aortic valve calcification (Agatston, volume & mass score as assessed by cardiac CT) has not been met according to results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 25 Mar 2022 Results published in the Clinical Cardiology